JP2013545820A5 - - Google Patents

Download PDF

Info

Publication number
JP2013545820A5
JP2013545820A5 JP2013544824A JP2013544824A JP2013545820A5 JP 2013545820 A5 JP2013545820 A5 JP 2013545820A5 JP 2013544824 A JP2013544824 A JP 2013544824A JP 2013544824 A JP2013544824 A JP 2013544824A JP 2013545820 A5 JP2013545820 A5 JP 2013545820A5
Authority
JP
Japan
Prior art keywords
independently
occurrence
alkyl
phosphonoxy
phosphono
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013544824A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013545820A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/065486 external-priority patent/WO2012083164A1/en
Publication of JP2013545820A publication Critical patent/JP2013545820A/ja
Publication of JP2013545820A5 publication Critical patent/JP2013545820A5/ja
Pending legal-status Critical Current

Links

JP2013544824A 2010-12-16 2011-12-16 抗ウイルス性化合物 Pending JP2013545820A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42390010P 2010-12-16 2010-12-16
US61/423,900 2010-12-16
PCT/US2011/065486 WO2012083164A1 (en) 2010-12-16 2011-12-16 Anti-viral compounds

Publications (2)

Publication Number Publication Date
JP2013545820A JP2013545820A (ja) 2013-12-26
JP2013545820A5 true JP2013545820A5 (enExample) 2015-02-12

Family

ID=45478542

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013544824A Pending JP2013545820A (ja) 2010-12-16 2011-12-16 抗ウイルス性化合物

Country Status (7)

Country Link
US (2) US20120115918A1 (enExample)
EP (1) EP2651924A1 (enExample)
JP (1) JP2013545820A (enExample)
CN (1) CN103384664A (enExample)
CA (1) CA2821973A1 (enExample)
MX (1) MX2013006828A (enExample)
WO (1) WO2012083164A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8546405B2 (en) 2008-12-23 2013-10-01 Abbott Laboratories Anti-viral compounds
RU2505540C2 (ru) 2008-12-23 2014-01-27 Эббви Инк. Антивирусные соединения
CA2758484A1 (en) * 2009-04-15 2010-10-21 David A. Degoey Anti-viral compounds
US8552047B2 (en) 2011-02-07 2013-10-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9546160B2 (en) 2011-05-12 2017-01-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
BR112014000563A2 (pt) 2011-07-09 2019-12-10 Sunshine Lake Pharma Co., Ltd composto, composição farmacêutica, e, uso do composto
US9326973B2 (en) 2012-01-13 2016-05-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
TWI610916B (zh) 2012-08-03 2018-01-11 廣東東陽光藥業有限公司 作爲丙型肝炎抑制劑的橋環化合物及其在藥物中的應用
WO2014082379A1 (en) 2012-11-29 2014-06-05 Sunshine Lake Pharma Co.,Ltd. Spiro ring compound as hepatitis c virus (hcv) inhibitor and uses thereof field of the invention
WO2014082380A1 (en) 2012-11-29 2014-06-05 Sunshine Lake Pharma Co., Ltd. Fused ring compounds as hepatitis c virus inhibitors, pharmaceutical compositions and uses thereof
US9717712B2 (en) 2013-07-02 2017-08-01 Bristol-Myers Squibb Company Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus
US20150023913A1 (en) 2013-07-02 2015-01-22 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US9775831B2 (en) 2013-07-17 2017-10-03 Bristol-Myers Squibb Company Combinations comprising biphenyl derivatives for use in the treatment of HCV
US10149859B2 (en) 2013-09-11 2018-12-11 Emory University Nucleotide and nucleoside therapeutic compositions and uses related thereto
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
WO2015110048A1 (en) 2014-01-23 2015-07-30 Sunshine Lake Pharma Co., Ltd. Bridged ring compounds as hepatitis c virus inhibitors, pharmaceutical compositions and uses thereof
WO2017023631A1 (en) 2015-08-06 2017-02-09 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
CN109689063A (zh) 2016-04-28 2019-04-26 埃默里大学 含有炔烃的核苷酸和核苷治疗组合物及其相关用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6037157A (en) 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
US7906655B2 (en) * 2008-08-07 2011-03-15 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
TWI438200B (zh) * 2009-02-17 2014-05-21 必治妥美雅史谷比公司 C型肝炎病毒抑制劑
CA2753313A1 (en) * 2009-02-23 2010-08-26 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
US8796466B2 (en) * 2009-03-30 2014-08-05 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CA2758484A1 (en) * 2009-04-15 2010-10-21 David A. Degoey Anti-viral compounds
US8138215B2 (en) * 2009-05-29 2012-03-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
AU2010274001A1 (en) * 2009-07-16 2012-02-23 Vertex Pharmaceuticals Incorporated Benzimidazole analogues for the treatment or prevention of Flavivirus infections

Similar Documents

Publication Publication Date Title
JP2013545820A5 (enExample)
JP2012524100A5 (enExample)
JP2012513409A5 (enExample)
RU2011146145A (ru) Противовирусные соединения
JP2013539791A5 (enExample)
JP2012513410A5 (enExample)
AR083398A1 (es) Compuestos antivirales
RU2015147447A (ru) Производные доластатина 10 и ауристатинов
JP2009531322A5 (enExample)
EA200900066A1 (ru) Кристаллические сольваты и комплексы производных (1s)-1,5-ангидро-1-c-(3-((фенил)метил)фенил) -d-глюцитола с аминокислотами в качестве ингибиторов sglt2 для лечения диабета
JP2008501000A5 (enExample)
JP2008531599A5 (enExample)
AR077060A1 (es) Compuestos antivirales
AR059425A1 (es) Amidas ciclicas condensadas del acido bencensulfonico, un metodo para su preparacion, composiciones farmaceuticas que las contienen y el empleo de las mismas en la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por la inhibicion de l-cpt1
JP2015520769A5 (enExample)
AU2017216429B2 (en) Use of sGC stimulators for the treatment of Nonalcoholic Steatohepatitis (NASH)
JP2013540713A5 (enExample)
JP2016516043A5 (enExample)
JP2011503118A5 (enExample)
RU2006133898A (ru) Производные бензимидазола и его применение
JP2013514367A5 (enExample)
RU2009118602A (ru) Производное индола
JP2016525136A5 (enExample)
JP2012511588A5 (enExample)
JP2017526677A5 (enExample)